Senolytic Treatment With Dasatinib and Quercetin Reshapes Influenza-Specific CD8 T Cell Responses During Infection in Aged, Vaccinated Mice.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41462563.
- Also identified by DOI 10.1111/acel.70345 and PMC identifier 12748518.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Older adults are disproportionately affected by infectious diseases like influenza (flu) due to immune declines and poor vaccine responses. Senolytics have been shown to improve various age-related conditions and positively influence infection outcomes, yet their potential to enhance vaccine responses has not yet been explored. Here, we evaluated the potential of senolytic combination Dasatinib (D) and Quercetin (Q) treatment prior to influenza vaccination to potentiate immune responses in aged mice. D + Q had minimal impact on overall vaccination and flu outcomes in vaccinated mice, including viral load and lung pathology. However, we observed altered CD8 T cell immunodominance and increased serum total PR8 (whole flu) IgG antibodies in D + Q treated vaccinated aged mice during infection. These findings reveal a new aspect of immunomodulation with senolytics.
Medical subject headings
- Quercetin
- Dasatinib
- CD8-Positive T-Lymphocytes
- Senotherapeutics
- Influenza Vaccines
- Orthomyxoviridae Infections
- Aging